INDIGO STAR (08373): Li Wenhao has been appointed as an independent non-executive director.

19:01 31/08/2026

Indigo Star (08373) announced that Dato Koh Yee Keng has resigned as the company's independent non-executive director, effective from August 31, 2026, due to his commitments to other businesses. Following his resignation as an independent non-executive director, Dato Koh Yee Keng will also cease to be a member of the company's Audit Committee, Remuneration Committee, and Chairman of the Nomination Committee, effective from August 31, 2026. Mr. Lee Wenhao has been appointed as an independent non-executive director, effective from September 1, 2026.

INDIGO STAR (08373) announced that Dato Koh Yee Keng has resigned as an independent non-executive director of the company, effective from August 31, 2026, due to his commitments to other businesses. Following his resignation as independent non-executive director, Dato Koh Yee Keng will no longer serve as a member of the companys audit committee, a member of the remuneration committee, and the chairman of the nomination committee, effective from August 31, 2026. Mr. Li Wenhao has been appointed as an independent non-executive director, effective from September 1, 2026.

BRIGHTSTAR TECH (08446) announced its interim results, with a profit attributable to shareholders of HKD 4.237 million, a decrease of 39.65% compared to the same period last year.

CSPC PHARMA (01093): The Phase I clinical trial of SYH2092 injection for weight management in adults with overweight or obesity has officially launched at the first research center in China.

XINKONG INT CAP (00993) announced its interim results, with a net loss attributable to equity holders of approximately HKD 341 million, narrowing by 31.43% year-on-year.

BRIGHTSTAR TECH (08446) announced its interim results, with a profit attributable to shareholders of HKD 4.237 million, a decrease of 39.65% compared to the same period last year.

CSPC PHARMA (01093): The Phase I clinical trial of SYH2092 injection for weight management in adults with overweight or obesity has officially launched at the first research center in China.

XINKONG INT CAP (00993) announced its interim results, with a net loss attributable to equity holders of approximately HKD 341 million, narrowing by 31.43% year-on-year.